143 related articles for article (PubMed ID: 36946312)
1. Intensity-modulated radiation therapy for intermediate-risk prostate cancer: does ADT still have an impact in the dose-escalated external beam radiation therapy era?
Soyano T; Kozuka T; Kashihara K; Murakami Y; Yonese J; Sasamura K; Shimoyachi N; Kashihara T; Yoshioka Y; Oguchi M
Jpn J Clin Oncol; 2023 Jun; 53(6):514-521. PubMed ID: 36946312
[TBL] [Abstract][Full Text] [Related]
2. The need for androgen deprivation therapy in patients with intermediate-risk prostate cancer treated with dose-escalated external beam radiation therapy.
Dong Y; Ruth KJ; Churilla TM; Viterbo R; Sobczak ML; Smaldone MC; Chen DY; Uzzo RG; Hallman MH; Horwitz EM
Can J Urol; 2017 Feb; 24(1):8656-8662. PubMed ID: 28263132
[TBL] [Abstract][Full Text] [Related]
3. Is androgen deprivation therapy necessary in all intermediate-risk prostate cancer patients treated in the dose escalation era?
Castle KO; Hoffman KE; Levy LB; Lee AK; Choi S; Nguyen QN; Frank SJ; Pugh TJ; McGuire SE; Kuban DA
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):693-9. PubMed ID: 22836052
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and prognostic factors in intermediate-risk prostate cancer: multi-institutional analysis of the Spanish RECAP database.
Hervás A; Pastor J; González C; Jové J; Gómez A; Casaña M; Villafranca E; Mengual JL; Muñoz V; Henriquez I; Muñoz J; Collado E; Clemente J
Clin Transl Oncol; 2019 Jul; 21(7):900-909. PubMed ID: 30536208
[TBL] [Abstract][Full Text] [Related]
5. Short-term ADT and Dose-escalated IMRT in Patients With Intermediate-risk Prostate Cancer: Benefit or Caution?
Post CM; Kahn JM; Turina CB; Beer TM; Hung AY
Am J Clin Oncol; 2022 May; 45(5):190-195. PubMed ID: 35446278
[TBL] [Abstract][Full Text] [Related]
6. Dose escalation for prostate cancer radiotherapy: predictors of long-term biochemical tumor control and distant metastases-free survival outcomes.
Zelefsky MJ; Pei X; Chou JF; Schechter M; Kollmeier M; Cox B; Yamada Y; Fidaleo A; Sperling D; Happersett L; Zhang Z
Eur Urol; 2011 Dec; 60(6):1133-9. PubMed ID: 21889832
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the effectiveness of adding androgen deprivation to modern dose-escalated radiotherapy for men with favorable intermediate-risk prostate cancer.
Falchook AD; Basak R; Mohiuddin JJ; Chen RC
Cancer; 2016 Aug; 122(15):2341-9. PubMed ID: 27191936
[TBL] [Abstract][Full Text] [Related]
8. High-dose radiotherapy with or without androgen deprivation therapy for intermediate-risk prostate cancer: cancer control and toxicity outcomes.
Edelman S; Liauw SL; Rossi PJ; Cooper S; Jani AB
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):1473-9. PubMed ID: 22245201
[TBL] [Abstract][Full Text] [Related]
9. Posttreatment Prostate-Specific Antigen 6 Months After Radiation With Androgen Deprivation Therapy Predicts for Distant Metastasis-Free Survival and Prostate Cancer-Specific Mortality.
Naik M; Reddy CA; Stephans KL; Ciezki JP; Garcia J; Grivas P; Stephenson AJ; Klein EA; Tendulkar RD
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):617-23. PubMed ID: 27681757
[TBL] [Abstract][Full Text] [Related]
10. Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.
Liauw SL; Stadler WM; Correa D; Weichselbaum RR; Jani AB
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):125-30. PubMed ID: 19695789
[TBL] [Abstract][Full Text] [Related]
11. Salvage of locally recurrent prostate cancer after external beam radiation using reduced-dose brachytherapy with neoadjuvant plus adjuvant androgen deprivation.
Baumann BC; Baumann JC; Christodouleas JP; Soffen E
Brachytherapy; 2017; 16(2):291-298. PubMed ID: 28139422
[TBL] [Abstract][Full Text] [Related]
12. Short-term androgen-deprivation therapy improves prostate cancer-specific mortality in intermediate-risk prostate cancer patients undergoing dose-escalated external beam radiation therapy.
Zumsteg ZS; Spratt DE; Pei X; Yamada Y; Kalikstein A; Kuk D; Zhang Z; Zelefsky MJ
Int J Radiat Oncol Biol Phys; 2013 Mar; 85(4):1012-7. PubMed ID: 22981709
[TBL] [Abstract][Full Text] [Related]
13. Assessing the impact of brachytherapy boost and androgen deprivation therapy on survival outcomes for patients with unfavorable intermediate-risk prostate cancer patients treated with external beam radiotherapy.
Andruska N; Agabalogun T; Fischer-Valuck BW; Brenneman RJ; Huang Y; Gay HA; Michalski JM; Carmona R; Baumann BC
Brachytherapy; 2022; 21(5):617-625. PubMed ID: 35641370
[TBL] [Abstract][Full Text] [Related]
14. Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer.
Morris WJ; Tyldesley S; Rodda S; Halperin R; Pai H; McKenzie M; Duncan G; Morton G; Hamm J; Murray N
Int J Radiat Oncol Biol Phys; 2017 Jun; 98(2):275-285. PubMed ID: 28262473
[TBL] [Abstract][Full Text] [Related]
15. Impact of radiation dose on recurrence in high-risk prostate cancer patients.
Deek M; Lilleby W; Vaage V; Hole KH; DeWeese T; Stensvold A; Tran P; Seierstad T
Prostate; 2020 Nov; 80(15):1322-1327. PubMed ID: 33258482
[TBL] [Abstract][Full Text] [Related]
16. Oncological outcomes for patients with locally advanced prostate cancer treated with neoadjuvant endocrine and external-beam radiation therapy followed by adjuvant continuous/intermittent endocrine therapy in an open-label, randomized, phase 3 trial.
Ito K; Kobayashi M; Komiyama M; Naito S; Nishimura K; Yonese J; Hashine K; Saito S; Arai G; Shinohara M; Masumori N; Shimizu N; Satoh T; Yamauchi A; Tochigi T; Takezawa Y; Fujimoto H; Yokomizo A; Kakimoto KI; Fukui I; Karasawa K; Tsukamoto T; Nozaki M; Hasumi M; Ishiyama H; Ohtani M; Kuwahara M; Harada M; Ohashi Y; Kotake T; Kakizoe T; Suzuki K; Yamanaka H;
Cancer; 2020 Sep; 126(17):3961-3971. PubMed ID: 32573779
[TBL] [Abstract][Full Text] [Related]
17. The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.
Shilkrut M; Merrick GS; McLaughlin PW; Stenmark MH; Abu-Isa E; Vance SM; Sandler HM; Feng FY; Hamstra DA
Cancer; 2013 Feb; 119(3):681-90. PubMed ID: 22893254
[TBL] [Abstract][Full Text] [Related]
18. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
19. Treatment outcomes of prostate cancer patients with Gleason score 8-10 treated with definitive radiotherapy : TROD 09-001 multi-institutional study.
Ozyigit G; Onal C; Igdem S; Alicikus ZA; Iribas A; Akin M; Yalman D; Cetin I; Aksu MG; Atalar B; Dincbas F; Hurmuz P; Guler OC; Aydin B; Sert F; Yildirim C; Gorken IB; Agaoglu FY; Korcum AF; Yuce D; Ozkok S; Darendeliler E; Akyol F
Strahlenther Onkol; 2019 Oct; 195(10):882-893. PubMed ID: 31143994
[TBL] [Abstract][Full Text] [Related]
20. Interval to biochemical failure predicts clinical outcomes in patients with high-risk prostate cancer treated by combined-modality radiation therapy.
Shilkrut M; McLaughlin PW; Merrick GS; Vainshtein JM; Feng FY; Hamstra DA
Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):721-8. PubMed ID: 23664325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
